Home Newsfeeds DA Davidson Reiterates Buy on Mattel, Maintains $23 Price Target

DA Davidson Reiterates Buy on Mattel, Maintains $23 Price Target

DA Davidson analyst Linda Bolton Weiser reiterates Mattel (NASDAQ:MAT) with a Buy and maintains $23 price target.

byBenzinga Newsdesk

March 9, 2023

1 minute read

DA Davidson analyst Linda Bolton Weiser reiterates Mattel (NASDAQ:MAT) with a Buy and maintains $23 price target.

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $65

By Benzinga Newsdesk

November 2, 5:12 AM

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.

HRMY

Vodafone’s Spain Unit Worth $4B Attracts Takeover Offers

By Anusuya Lahiri

April 5, 10:46 AM

Vodafone Group Plc’s (NASDAQ:VOD) Spanish business worth over $4 billion draws takeover interest from potential buyers. Private equity and strategic…

LBTYA

H.B. Fuller Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

By Avi Kapoor

March 27, 5:03 AM

H.B. Fuller Company (NYSE: FUL) is expected to release earnings results for its first quarter, after the closing bell on March 28, 2024.

FUL

After Brain Cancer Data, Candel Therapeutics’ Shares Good News From Pancreatic Cancer Study

By Vandana Singh

April 4, 10:24 AM

Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5 months.

CADL

DA Davidson Reiterates Buy on Mattel, Maintains $23 Price Target

Related Posts

Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $65

Vodafone’s Spain Unit Worth $4B Attracts Takeover Offers

H.B. Fuller Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

After Brain Cancer Data, Candel Therapeutics’ Shares Good News From Pancreatic Cancer Study